The disconnect between payers and pharma companies is just one symptom of pharma’s outdated business model, according to Janssen’s company group chairman EMEA, Kris Sterkens.
Doug Danison, vice-president, head of access, value and evidence strategy at bluebird bio, a gene therapy company, looks at the obstacles, opportunities and required change in thinking need
NHS England is no longer the new kid on the block, taking up its role in 2013. In 2019, NHS England is a commercially savvy organisation when it comes to all things to do with medicines.
